Organogenesis Holdings Inc. ORGO R2KR3KPHARMA
Company Overview
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Why Investors Should Care
Net profit has compounded at 16.5% per year over the last five years.
Revenue has grown at a 16.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.19.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $564.17M (+17.0% YoY); net profit $37.03M.
- Trailing 12 Months Year-on-year growth — revenue -57.1%, earnings +4201.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.9%, profit CAGR 16.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.87% |
| 1 Year: | -57.10% |
Compounded Profit Growth
| 5 Years: | 16.53% |
| 1 Year: | 4,201.05% |
Stock Price Performance
| 1 Year: | -65.17% |
| 6 Months: | -38.71% |
| 3 Months: | -29.34% |
| 1 Month: | -29.05% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.55 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 16.9% over 5 years.
- Profit CAGR of 16.5% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 73.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ORGO Organogenesis Holdings Inc. R2KR3KPHARMA | 1.71 | -14.25 | $220.03M | 0.00% | 8.96% | 0.73% | 16.87% | 16.53% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 39.84M | 54.07M | 51.46M | 53.14M | 35.53M | 43.55M | 50.77M | 63.60M | 57.12M | 64.95M | 64.27M | 61.73M | 68.96M | 100.80M | 102.55M | 123.20M | 113.75M | 97.12M | 121.40M | 116.86M | 107.64M | 117.32M | 108.53M | 109.98M | 130.23M | 115.18M | 86.69M | 101.00M | 150.86M | 37.23M | 43.76M |
| Gross Profit | - | - | - | - | 26.53M | 38.66M | 35.37M | 36.72M | 21.01M | 26.25M | 31.29M | 46.09M | 40.14M | 45.50M | 45.13M | 42.94M | 48.92M | 77.83M | 77.06M | 93.26M | 87.59M | 72.04M | 94.75M | 90.68M | 81.03M | 91.00M | 82.74M | 81.28M | 101.04M | 88.38M | 62.97M | - | - | - | - |
| Operating Income | -15.55K | -500 | -14.49K | -1.30M | -2.97M | 2.50M | -2.62M | -2.40M | -19.98M | -17.02M | -10.07M | -4.48M | -12.12M | -7.32M | -8.27M | -15.08M | -2.25M | 22.80M | 12.62M | 23.59M | 16.26M | -128.00K | 11.94M | 1.78M | -4.00M | 9.74M | 8.05M | -3.85M | -13.89M | 6.24M | -26.75M | -12.58M | 20.73M | -68.89M | -50.99M |
| Net Income | -15.55K | -500 | -14.49K | -178.16K | 2.27M | 31.00K | -5.40M | -4.43M | -22.49M | -20.01M | -13.08M | -9.26M | -15.67M | -9.65M | -10.74M | -16.31M | -5.17M | 20.75M | 9.94M | 20.69M | 12.58M | -913.00K | 8.74M | 215.00K | -2.97M | 5.32M | 3.17M | -2.10M | -17.04M | 12.33M | -18.84M | -9.39M | 21.57M | -53.16M | -96.27M |
| Diluted EPS | - | - | - | - | 0.02 | 0.00 | -0.08 | -0.07 | - | - | - | - | - | - | -0.12 | -0.16 | -0.05 | 0.19 | 0.07 | 0.15 | 0.09 | -0.01 | 0.07 | 0.00 | -0.02 | 0.04 | 0.02 | -0.02 | -0.13 | 0.09 | -0.17 | -0.10 | 0.11 | -0.44 | -0.77 |
| R&D Expense | - | - | - | - | 1.55M | 2.45M | 2.33M | 2.73M | 2.82M | 2.05M | 2.78M | 3.09M | 3.37M | 3.86M | 3.92M | 5.41M | 4.67M | 3.71M | 6.21M | 7.32M | 8.95M | 8.59M | 10.21M | 9.57M | 11.20M | 10.94M | 10.47M | 12.81M | 15.59M | 10.34M | 10.64M | 10.39M | 13.22M | 15.16M | 18.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 138.73M | 198.51M | 193.45M | 260.98M | 338.30M | 467.36M | 450.89M | 433.14M | 482.04M | 564.17M |
| Gross Profit | 90.53M | 137.29M | 124.64M | 185.03M | 250.98M | 353.16M | 345.87M | 326.66M | 366.30M | - |
| Operating Income | -8.78M | -5.49M | -51.56M | -29.85M | 26.70M | 72.22M | 22.30M | 12.53M | -1.28M | 44.69M |
| Net Income | -16.99M | -8.39M | -64.83M | -38.71M | 17.23M | 94.20M | 15.53M | 4.95M | 861.00K | 37.03M |
| Diluted EPS | - | - | -0.94 | -0.42 | 0.15 | 0.70 | 0.12 | 0.04 | -0.01 | 0.15 |
| R&D Expense | 6.28M | 9.06M | 10.74M | 14.80M | 20.09M | 30.74M | 39.76M | 44.38M | 50.27M | 44.54M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 416.27K | 311.44M | 148.72M | 163.68M | 220.69M | 290.22M | 443.26M | - | 449.36M | 460.02M | 497.89M | 598.73M |
| Total Equity | 3.51M | -15.98M | -15.32M | 39.94M | 52.02M | 141.81M | 241.34M | 241.53M | 265.67M | 278.66M | 262.90M | 300.13M |
| Cash & Equivalents | - | - | - | - | - | 84.39M | 113.93M | - | 102.48M | 103.84M | 135.57M | 93.68M |
| Long Term Debt | - | - | 52.14M | - | 49.63M | 70.00M | 74.06M | - | 71.25M | 66.56M | - | - |
| Total Liabilities | 416.43K | 11.33M | 157.28M | 116.64M | 165.10M | 148.41M | 201.92M | 194.74M | 183.69M | 181.36M | 112.57M | 164.81M |
| Current Liabilities | 416.43K | 478.36K | 51.97M | 56.10M | 59.89M | 68.22M | 82.70M | 78.49M | 75.02M | 80.51M | 77.48M | 100.12M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.87M | -3.49M | -60.63M | -33.53M | 5.47M | 61.98M | 24.86M | 30.92M | 14.21M | -10.31M |
| Investing Cash Flow | -1.25M | -14.87M | -1.86M | -6.23M | -23.50M | -31.22M | -33.90M | -24.36M | -10.03M | -14.15M |
| Financing Cash Flow | 6.78M | 18.87M | 81.54M | 78.73M | 42.47M | -1.04M | -2.20M | -5.50M | 27.64M | -17.36M |
| Capital Expenditure | -1.36M | -2.43M | -1.86M | -5.98M | -17.68M | -31.22M | -33.90M | -24.36M | -10.03M | -14.15M |
| Free Cash Flow | -6.23M | -5.92M | -62.49M | -39.51M | -12.21M | 30.76M | -9.04M | 6.55M | 4.18M | -24.46M |
| Share Buybacks | - | - | - | - | - | - | 0 | 0 | 25.48M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 65.3% | 69.2% | 64.4% | 70.9% | 74.2% | 75.6% | 76.7% | 75.4% | 76.0% | - |
| Operating Margin % | -6.3% | -2.8% | -26.7% | -11.4% | 7.9% | 15.5% | 4.9% | 2.9% | -0.3% | 7.9% |
| Net Margin % | -12.2% | -4.2% | -33.5% | -14.8% | 5.1% | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% |
| ROE % | 106.3% | 54.8% | -162.3% | -74.4% | 12.2% | 39.0% | 5.8% | 1.8% | 0.3% | 12.3% |
| ROCE % | -2.8% | -5.7% | -47.9% | -18.6% | 12.0% | 20.0% | 6.0% | 3.3% | -0.3% | 9.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Morgan Stanley | 9.11% | 11.72M | $20.40M |
| 2 | Soleus Capital Management, L.P. | 7.88% | 10.14M | $17.65M |
| 3 | Blackrock Inc. | 5.63% | 7.25M | $12.61M |
| 4 | Dimensional Fund Advisors LP | 2.37% | 3.05M | $5.31M |
| 5 | AQR Capital Management, LLC | 2.34% | 3.01M | $5.24M |
| 6 | Vanguard Capital Management LLC | 2.26% | 2.91M | $5.06M |
| 7 | Shaw D.E. & Co., Inc. | 2.24% | 2.89M | $5.03M |
| 8 | Assenagon Asset Management S.A. | 1.53% | 1.97M | $3.42M |
| 9 | Geode Capital Management, LLC | 1.50% | 1.94M | $3.37M |
| 10 | Deutsche Bank AG | 1.33% | 1.71M | $2.97M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ORGO
Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPdmI1UWV0dXc1LWJhRUZQcXVQbklKRnhCXzV6UklOMTZIRlY5TE1BWnJQalAyS1M0X0c4b2hDQ2ZOMEN3Y3lQbFRvMEFHVkhJRzR2MHEwNko3bHFLcUt6b052RmJFbm9OZVpZb0liaXpzdDNrRWZBMTNpTEl6eEJ2WklybUxVekZRTjB5VT…
ORGO Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9hTWYtMlVkbnp1T181R1pSOTdTdDhVRTFHREVWdzVONHBwMF9mUFFMQlV1aXBhVThZWmdhX2ZVS1RHNV9RRVV0SnlOa1VKNzNUSmNIeEM0blZ1Q2NTb2tOUzVYakpYc1NGbEtocDhlUi0zUWZzMGNfa1Rn?oc=5" target="_blank">ORG…
Organogenesis (ORGO) Stock Price Sinks On Deeper Losses And Margin Crunch - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPZEZJQ3JGN2FPa0V3Y2V2ZFJIc2JTUy03dDdOOFF0MkV0bXcya3ZOV0dsMUVBMEEzbkV2bTE4MjZUZFNZQk94M05pSGdOWVI4QUVLeTdKUmxpbUNlaTU2Ul9UVjZnYWVjajVCaExOZS13aW5KeTJwdDRlYU9abS1RdUZtX0Jzd1pzbHJIRU…
Organogenesis (Nasdaq: ORGO) sets up $75M at-the-market stock sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQU1ZZQzQxTDNNUlRFcE9kdDdCMGVfS3NUS1dneTNfT2JaRjcwaXhpdWlSQVM4Slc0Q201R1hGZ0lHZFplaVdjT3JSeUFnbnJ2WFhQbE44ODY1YWVQSTJlM2hhLXk5U1FnbWF2azdZYTJCUmRVekFlMVZFZ0RwR0lfaGVsdFVpMmpTVmVtUG…
ORGO - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBFWThjZzJGTE94TGRKN2wzQ2htNTFOcnFhamd6c0lrMEE5RzNEclk1UkMwc3UtUlFWUENJcHc5QkU5YUJMZ1E?oc=5" target="_blank">ORGO</a> <font color="#6f6f6f">Finviz</font>…
ORGO Stock Rallies After Hours On Clearing Regulatory Pathway For Pain Relief Treatment - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxPbjh3a1hSeWpFa3ZTaHh3VFdERTUxbGJ6czJDMDdlZVNWeGFjLXBiZkY0V0lzNDJxNU5SUFVhMlkxd29nWXRMOGxiLTl6bzZQU3F5QnY3ZDNuSVhOYk03NElqeDcwUGhsTl9RTzRFQnBMNUY4NGhVU2NpNTNpR1Z3Z1dQcFpqQmJla191RW…
ORGO — Frequently Asked Questions
What is the current share price of Organogenesis Holdings Inc. (ORGO)?
As of 2026-09-07 16:24 PDT, Organogenesis Holdings Inc. (ORGO) trades at $1.71 on NasdaqCM. Its 52-week range is $1.63 to $6.54.
What is the market capitalisation of ORGO?
Organogenesis Holdings Inc. (ORGO) has a market capitalisation of $220.03M on NasdaqCM.
What is the P/E ratio of ORGO?
ORGO trades at a trailing price-to-earnings (P/E) ratio of -14.25. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.98.
What is the return on equity (ROE) of ORGO?
ORGO has a return on equity (ROE) of 0.73%. Its return on capital employed (ROCE) is 8.96%.
Is ORGO a good stock to buy?
This page provides a data-driven analysis of Organogenesis Holdings Inc. (ORGO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.